Stephan Lauxmann

Dr. Stephan Lauxmann


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
HHHenrike O. Heyne
Henrike O. Heyne
DBDavid Baez-Nieto
David Baez-Nieto
SISumaiya Iqbal
Sumaiya Iqbal
DPDuncan S. Palmer
Duncan S. Palmer
ABAndreas Brunklaus
Andreas Brunklaus
MDMark J. Daly
Mark J. Daly
A machine learning method can predict loss- versus gain-of-function effects of human genetic variants in disease-associated ion channels.

1 September 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
UHUlrike B. S. Hedrich
Ulrike B. S. Hedrich
SLStephan Lauxmann
Stephan Lauxmann
MWMarkus Wolff
Markus Wolff
MSMatthis Synofzik
Matthis Synofzik
TBThomas Bast
Thomas Bast
HLHolger Lerche
Holger Lerche
4-Aminopyridine is a potential therapeutic option for a subgroup of patients with KCNA2 -encephalopathy and gain-of-function variants.

24 August 2018 in Human Mutation
Verified
Journal Article
Closed access
PDF file
SLStephan Lauxmann
Stephan Lauxmann
NVNienke E. Verbeek
Nienke E. Verbeek
YLYuanyuan Liu
Yuanyuan Liu
MZMariana Zaichuk
Mariana Zaichuk
SMStephan Müller
Stephan Müller
UHUlrike B.S. Hedrich
Ulrike B.S. Hedrich

1 July 2024 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
SLStephan Lauxmann
Stephan Lauxmann
DHDavid Heuer
David Heuer
JHJan Heckelmann
Jan Heckelmann
FFFlorian P. Fischer
Florian P. Fischer
MSMelanie Schreiber
Melanie Schreiber
SWStefan Wolking
Stefan Wolking
Background: Clinical trials have shown that cenobamate (CNB) is an efficacious and safe anti-seizure medication (ASM) for drug-resistant focal epilepsy. Here, we analyzed one of the largest real-world cohorts, covering the entire spectrum of epilepsy syndromes, the efficacy and safety of CNB, and resulting changes in concomitant ASMs. Methods: We conducted a retrospective observational study investigating CNB usage in two German tertiary referral centers between October 2020 and June 2023 with follow-up data up to 27 months of treatment. Our primary outcome was treatment response. Secondary outcomes comprised drug response after 12 and 18 months, seizure freedom rates, CNB dosage and retention, adverse drug reactions (ADRs), and changes in concomitant ASMs. Results: 116 patients received CNB for at least two weeks. At 6 months, 98 patients were eligible for evaluation. Thereof 50% (49/98) were responders with no relevant change at 12 and 18 months. Seizure freedom was achieved in 18.4% (18/98) at 6 months, 16.7% (11/66), and 3.0% (1/33) at 12 and 18 months. The number of previous ASMs did not affect the seizure response rate. Overall, CNB was well-tolerated, however, in 7.7% (9/116), ADRs led to treatment discontinuation. The most frequent changes of concomitant ASMs included the discontinuation or reduction of sodium channel inhibitors, clobazam reduction, and perampanel discontinuation, while brivaracetam doses were usually left unchanged. Conclusions: CNB proved to be a highly effective and generally well-tolerated ASM in patients with severe drug-resistant epilepsy, comprising a broad array of epilepsy syndromes beyond focal epilepsy.

9 September 2021 in Frontiers in Neurology
Verified
Journal Article
Open access
SLStephan Lauxmann
Stephan Lauxmann
LSLukas Sonnenberg
Lukas Sonnenberg
NKNils A. Koch
Nils A. Koch
CBChristian Bosselmann
Christian Bosselmann
NWNatalie Winter
Natalie Winter
JKJosua Kegele
Josua Kegele
Introduction: Among genetic paroxysmal movement disorders, variants in ion channel coding genes constitute a major subgroup. Loss-of-function (LOF) variants in KCNA1, the gene coding for KV1.1 channels, are associated with episodic ataxia type 1 (EA1), characterized by seconds to minutes-lasting attacks including gait incoordination, limb ataxia, truncal instability, dysarthria, nystagmus, tremor, and occasionally seizures, but also persistent neuromuscular symptoms like myokymia or neuromyotonia. Standard treatment has not yet been developed, and different treatment efforts need to be systematically evaluated.Objective and Methods: Personalized therapeutic regimens tailored to disease-causing pathophysiological mechanisms may offer the specificity required to overcome limitations in therapy. Toward this aim, we (i) reviewed all available clinical reports on treatment response and functional consequences of KCNA1 variants causing EA1, (ii) examined the potential effects on neuronal excitability of all variants using a single compartment conductance-based model and set out to assess the potential of two sodium channel blockers (SCBs: carbamazepine and riluzole) to restore the identified underlying pathophysiological effects of KV1.1 channels, and (iii) provide a comprehensive review of the literature considering all types of episodic ataxia.Results: Reviewing the treatment efforts of EA1 patients revealed moderate response to acetazolamide and exhibited the strength of SCBs, especially carbamazepine, in the treatment of EA1 patients. Biophysical dysfunction of KV1.1 channels is typically based on depolarizing shifts of steady-state activation, leading to an LOF of KCNA1 variant channels. Our model predicts a lowered rheobase and an increase of the firing rate on a neuronal level. The estimated concentration dependent effects of carbamazepine and riluzole could partially restore the altered gating properties of dysfunctional variant channels.Conclusion: These data strengthen the potential of SCBs to contribute to functional compensation of dysfunctional KV1.1 channels. We propose riluzole as a new drug repurposing candidate and highlight the role of personalized approaches to develop standard care for EA1 patients. These results could have implications for clinical practice in future and highlight the need for the development of individualized and targeted therapies for episodic ataxia and genetic paroxysmal disorders in general.

19 December 2022 in British Journal of Pharmacology
Verified
Journal Article
Open access
EBErva Bayraktar
Erva Bayraktar
YLYuanyuan Liu
Yuanyuan Liu
LSLukas Sonnenberg
Lukas Sonnenberg
UHUlrike B. S. Hedrich
Ulrike B. S. Hedrich
YSYildirim Sara
Yildirim Sara
SLStephan Lauxmann
Stephan Lauxmann
Background and Purpose: Variants in SCN8A, the NaV1.6 channel's coding gene, are characterized by a variety of symptoms, including intractable epileptic seizures, psychomotor delay, progressive cognitive decline, autistic features, ataxia or dystonia. Standard anticonvulsant treatment has a limited impact on the course of disease.Experimental Approach: We investigated the therapeutic potential of eslicarbazepine (S‐licarbazepine; S‐lic), an enhancer of slow inactivation of voltage gated sodium channels, on two variants with biophysical and neuronal gain‐of‐function (G1475R and M1760I) and one variant with biophysical gain‐of‐function but neuronal loss‐of‐function (A1622D) in neuroblastoma cells and in murine primary hippocampal neuron cultures. These three variants cover the broad spectrum of NaV1.6‐associated disease and are linked to representative phenotypes of mild to moderate epilepsy (G1475R), developmental and epileptic encephalopathy (M1760I) and intellectual disability without epilepsy (A1622D).Key Results: Similar to known effects on NaV1.6 wildtype channels, S‐lic predominantly enhances slow inactivation on all tested variants, irrespective of their particular biophysical mechanisms. Beyond that, S‐lic exhibits variant‐specific effects including a partial reversal of pathologically slowed fast inactivation dynamics (A1622D and M1760I) and a trend to reduce enhanced persistent Na+ current by A1622D variant channels. Furthermore, our data in primary transfected neurons reveal that not only variant‐associated hyperexcitability (M1760I and G1475R) but also hypoexcitability (A1622D) can be modulated by S‐lic.Conclusions and Implications: S‐lic has not only substance‐specific effects but also variant‐specific effects. Personalized treatment regimens optimized to achieve such variant‐specific pharmacological modulation may help to reduce adverse side effects and improve the overall therapeutic outcome of SCN8A‐related disease.